Kanopas 20 mg (Tablet)
Unit Price: ৳ 120.00 (1 x 10: ৳ 1,200.00)
Strip Price: ৳ 1,200.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Finerenone |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- Reduce risk of sustained eGFR decline
- Reduce risk of end-stage kidney disease
- Reduce risk of cardiovascular death
- Reduce risk of nonfatal myocardial infarction
- Reduce risk of hospitalization for heart failure
Pharmacology
- Nonsteroidal
- Selective antagonist of mineralocorticoid receptor (MR)
- Blocks MR mediated sodium reabsorption
- High potency and selectivity for MR
- No relevant affinity for androgen, progesterone, estrogen, and glucocorticoid receptors
- Mean systolic blood pressure decrease by 3 mmHg
- Mean diastolic blood pressure decrease by 1-2 mmHg
- Completely absorbed after oral administration
- Undergoes metabolism with absolute bioavailability of 44%
- Steady state achieved after 2 days of dosing
- Metabolized by CYP3A4 (90%) and CYP2C8 (10%) to inactive metabolites
- 80% of the administered dose excreted in urine
Dosage & Administration
- Recommended starting dosage of 10 mg or 20 mg orally once daily
- Tablets may be taken with or without food
- For patients unable to swallow whole tablets, can be crushed and mixed with water or soft foods
- Monitor serum potassium 4 weeks after initiating treatment and adjust dose accordingly
- Missed doses should be taken as soon as possible on the same day
Interaction
- Contraindicated with strong CYP3A4 inhibitors
- Cautious with moderate and weak CYP3A4 inhibitors
- Avoid concomitant use with strong or moderate CYP3A4 inducers
- Avoid concomitant intake of grapefruit or grapefruit juice
Contraindications
- Contraindicated in concomitant use with strong CYP3A4 inhibitors
- Contraindicated in patients with adrenal insufficiency
Side Effects
- Adverse reactions include hyperkalemia, hypotension, and hyponatremia
Pregnancy & Lactation
- No available data on use in pregnancy
- Avoid breastfeeding during treatment and for 1 day after treatment
Precautions & Warnings
- Can cause hyperkalemia
- Measure serum potassium and eGFR before initiation of treatment
- Do not initiate if serum potassium is > 5.0 mEq/L
- More frequent monitoring may be necessary for patients at risk for hyperkalemia
Use in Special Populations
- Safety and efficacy not established in patients below 18 years of age
- No overall differences in safety or efficacy observed in geriatric patients
- Avoid use in patients with severe hepatic impairment
Overdose Effects
- Suspected overdose should be immediately interrupted
- The most likely manifestation of overdose is hyperkalemia
- Standard treatment for hyperkalemia should be initiated
Therapeutic Class
- Mineralocorticoid Receptor Antagonists
Storage Conditions
- Keep below 30°C temperature
- Keep away from light and moisture
- Keep out of the reach of children